©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4289-4297
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4289
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4289
Conversion therapy for unresectable hepatocellular carcinoma: Advances and challenges
Yan-Fei He, Department of Health Management Center, The Sixth Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100048, China
Author contributions: He YF designed the study, collected the data, reviewed the literature, drafted and revised the manuscript, and have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Yan-Fei He, MD, Associate Chief Physician, Doctor, Department of Health Management Center, The Sixth Medical Center, Chinese People’s Liberation Army General Hospital, No. 6 Fucheng Road, Haidian District, Beijing 100048, China.
Received: March 2, 2024
Revised: August 29, 2024
Accepted: September 5, 2024
Published online: October 15, 2024
Processing time: 208 Days and 6.4 Hours
Revised: August 29, 2024
Accepted: September 5, 2024
Published online: October 15, 2024
Processing time: 208 Days and 6.4 Hours
Core Tip
Core Tip: This letter reviews recent advances in conversion therapy for hepatocellular carcinoma (HCC), comparatively describes the characteristics of different conversion programs, addresses current challenges in conversion therapy, highlights the complexity of conversion therapy for moderately advanced HCC, and emphasizes the importance of a multidisciplinary, team-based management model, and provides valuable insights into the treatment of unresectable HCC.